Immunosuppressive minimization with mTOR inhibitors and belatacept

Transplant International

Volumn 28, Issue 8, 2015, Pages 921-927

  Diekmann, Fritz ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

clinical immunosuppression; costimulation blockade; mTOR inhibition

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; RAPAMYCIN; ABATACEPT; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT PLANNING; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PROCEDURES;

ABATACEPT; CALCINEURIN INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVEROLIMUS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84947032895     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12603     Document Type: Review

References (38)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
3. Einecke G, Sis B, Reeve J, et al,. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520.
4. Vincenti F, Friman S, Scheuermann E, et al,. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
5. Kasiske BL, Anjum S, Shah R, et al,. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
6. Hjelmesaeth J, Hartmann A, Kofstad J, Egeland T, Stenstrom J, Fauchald P,. Tapering off prednisolone and cyclosporin the first year after renal transplantation: the effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829.
7. Hjelmesaeth J, Hartmann A, Midtvedt K, et al,. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant 2001; 16: 1047.
8. Veenstra D, Best JH, Hornberger J, Sullivan SD, Hricik DE,. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829.
9. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN,. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009; 35: 148.
10. Kahan BD,. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194.
11. Larsen CP, Pearson TC, Adams AB, et al,. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
12. Janeway CA, Bottomly K,. Signals and signs for lymphocyte responses. Cell 1994; 76: 275.
13. June CH, Bluestone JA, Nadler LM, Thompson CB,. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321.
14. Walunas TL, Bakker CY, Bluestone JA,. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996; 183: 2541.
15. Tang Q, Henriksen KJ, Boden EK, et al,. Cutting edge: CD28 controls peripheral homeostasis of CD4 + CD25 + regulatory T cells. J Immunol 2003; 171: 3348.
16. Salomon B, Lenschow DJ, Rhee L, et al,. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25 + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431.
17. Bour-Jordan H, Bluestone JA,. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev 2009; 229: 41.
18. Bestard O, Cassis L, Cruzado JM, et al,. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int 2011; 24: 451.
19. Singh K, Kozyr N, Stempora L, et al,. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 2012; 12: 1441.
20. Lo DJ, Anderson DJ, Weaver TA, et al,. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 2013; 13: 320.
21. Flechner SM, Kurian SM, Solez K, et al,. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
22. Flechner SM, Glyda M, Cockfield S, et al,. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633.
23. Peddi VR, Wiseman A, Chavin K, Slakey D,. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando) 2013; 27: 97.
24. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
25. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
26. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
27. Weir MR, Mulgaonkar S, Chan L, et al,. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897.
28. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
29. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
30. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
31. Vincenti F, Larsen CP, Alberu J, et al,. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210.
32. Vincenti F, Blancho G, Durrbach A, et al,. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587.
33. Pestana JO, Grinyo JM, Vanrenterghem Y, et al,. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630.
34. Rostaing L, Massari P, Garcia VD, et al,. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6: 430.
35. Grinyo J, Alberu J, Contieri FL, et al,. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int 2012; 25: 1059.
36. Ferguson R, Grinyo J, Vincenti F, et al,. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011; 11: 66.
37. Kirk AD, Guasch A, Xu H, et al,. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant 2014; 14: 1142.
38. Bluestone JA, Liu W, Yabu JM, et al,. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.